BridgeBio Oncology Therapeutics Inc.
BBOT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $73,107 | $56,286 | $0 | $0 |
| G&A Expenses | $7,756 | $8,485 | $0 | $0 |
| SG&A Expenses | $7,756 | $8,485 | $4 | $43 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $80,863 | $64,771 | $4 | $43 |
| Operating Income | -$80,863 | -$64,771 | -$4 | -$43 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $6,588 | $72 | $0 | $0 |
| Pre-Tax Income | -$74,275 | -$64,699 | -$4 | -$43 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$74,275 | -$64,699 | -$4 | -$43 |
| % Margin | – | – | – | – |
| EPS | 0.46 | -0.002 | 0 | -0.002 |
| % Growth | 23,100% | – | 100% | – |
| EPS Diluted | 0.46 | -0.002 | 0 | -0.002 |
| Weighted Avg Shares Out | 16,636 | 20,485 | 20,485 | 20,485 |
| Weighted Avg Shares Out Dil | 16,636 | 20,485 | 20,485 | 20,485 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,455 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $208 | $92 | $0 | $0 |
| EBITDA | -$80,655 | -$64,679 | -$4 | -$43 |
| % Margin | – | – | – | – |